Management of Hypercalcemia

Severity Classification

Step 1: Immediate General Measures (All Severity Levels)

• Discontinue offending agents: calcium supplements, thiazide diuretics, lithium, vitamin D, antacids
• Avoid immobility - weight-bearing activity reduces bone resorption
• Ensure adequate hydration - oral fluids for mild cases
• Remove calcium from IV solutions and diet

Step 2: Acute Management

A. IV Saline Rehydration - FIRST AND MOST IMPORTANT STEP

• Dose: 200-500 mL/hour of isotonic (0.9%) saline, adjusted for cardiovascular/renal status
• Target: Urine output of 100-200 mL/hour
• Effect: Lowers calcium by ~1-3 mg/dL by increasing GFR and reducing tubular calcium reabsorption
• Caution: Monitor closely for volume overload, especially in patients with heart failure or renal insufficiency

B. Loop Diuretics

• Furosemide: 20-80 mg IV (escalating doses); alternatively 40-80 mg every 6 hours
• Mechanism: Blocks the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb, increasing calciuresis
• Effect: Together with saline, can lower calcium by 2-4 mg/dL
• Electrolyte replacement: Replace urinary losses of K⁺ (20-40 mEq/L) and Mg²⁺ (15-30 mg/L) to prevent hypokalemia and hypomagnesemia - check every 2-4 hours
• Note: Loop diuretics for hypercalcemia are not supported by RCTs and have fallen out of favor for routine use - they are reserved for life-threatening hypercalcemia with adequate volume status

Step 3: First-Line Anti-Resorptive Therapy - IV Bisphosphonates

• Zoledronate is more potent and has a shorter infusion time - preferred in malignancy
• For severe hypercalcemia (>13.5 mg/dL), use pamidronate 90 mg
• Treatment can be repeated after 7 days if hypercalcemia recurs
• Renal impairment: Use with caution if creatinine >2.5-3.0 mg/dL; zoledronate is contraindicated for GFR <30 mL/min
• Adverse effects: Transient flu-like syndrome (fever, chills, myalgias), acute kidney injury, osteonecrosis of the jaw (chronic use)

Step 4: Adjunctive Agents

Calcitonin - Fastest Acting

• Salmon calcitonin: 4-8 IU/kg IM or SC every 6-12 hours
• Effect: Lowers calcium by 1-2 mg/dL within a few hours in 60-70% of patients
• Advantages: Safe in renal failure; may have analgesic effect in skeletal metastases; no serious toxicity
• Limitation: Tachyphylaxis ("escape phenomenon") occurs within 48-72 hours - not for long-term use
• Use: Bridge therapy while waiting for bisphosphonates to take effect; or when bisphosphonates are contraindicated

Glucocorticoids

• Prednisone: 20-60 mg/day PO (up to 40-100 mg in divided doses for malignancy) or IV equivalent
• Mechanism: Inhibit 1-alpha-hydroxylase (reducing calcitriol) and decrease intestinal calcium absorption
• Best for:
  • Hematologic malignancies (lymphoma, myeloma, leukemia)
  • Granulomatous diseases (sarcoidosis, TB) causing excess calcitriol production
  • Vitamin D toxicity
• Onset: Slow (4-10 days)
• Adverse effects: Hyperglycemia, hypokalemia, hypertension, immunosuppression, Cushing syndrome

Oral Phosphorus

• Dose: 250 mg (e.g., Neutra-Phos) 3-4 times daily
• Target: Until serum phosphorus >3 mg/dL
• Used adjunctively in humoral hypercalcemia of malignancy (PTHrP-driven)

Step 5: Second-Line / Refractory Hypercalcemia

Denosumab

• Mechanism: Humanized monoclonal antibody against RANK ligand (anti-RANKL) - prevents osteoclast activation
• Dose: 120 mg SC on days 1, 8, 15, 29, then monthly; or 60-120 mg SC depending on indication
• Key indications:
  • Bisphosphonate-refractory hypercalcemia
  • Chronic kidney disease / AKI (safer than bisphosphonates when GFR <30)
  • Bone resorption-associated hypercalcemia in malignancy
• Adverse effects: Hypocalcemia (can be severe post-discontinuation), hypophosphatemia, osteonecrosis of the jaw, atypical femoral fractures
• Caution: Rebound hypercalcemia reported after discontinuation in osteoporosis patients [PMID: 41571922]

Cinacalcet

• Mechanism: Activates calcium-sensing receptor (calcimimetic) - suppresses PTH secretion
• Dose: 30 mg PO twice daily up to 90 mg PO four times daily
• Best for: Primary hyperparathyroidism (patients not surgical candidates), parathyroid carcinoma, ectopic PTH-secreting tumors
• Effect: Reduces PTH and serum calcium levels

Gallium Nitrate

• 100-200 mg/m² IV continuous infusion over 24 hours for 5 days
• Inhibits bone resorption by reducing osteoclast activity
• Limited by nephrotoxicity

Mithramycin (Plicamycin)

• Single dose of 25 mcg/kg over 4-6 hours
• Largely obsolete now that bisphosphonates and denosumab are available
• Serious toxicity: thrombocytopenia, hepatitis, renal failure

Step 6: Dialysis - Severe/Refractory Cases

• Indications: Serum calcium >16 mg/dL + CHF, oliguria, or severe renal insufficiency; when saline hydration and bisphosphonates are too slow or contraindicated
• Method: Hemodialysis or peritoneal dialysis with low-calcium dialysate
• Provides rapid calcium removal when pharmacologic options are insufficient

Chronic Management by Etiology

Primary Hyperparathyroidism

1. Corrected serum Ca²⁺ >1.0 mg/dL above the upper limit of normal
2. Creatinine clearance <60 mL/min
3. Age <50 years
4. Bone mineral density T-score < -2.5 at hip, lumbar spine, or distal radius, or previous fragility fracture

• Success rate: ~95% with low morbidity/mortality

• Liberal oral hydration + high-salt diet
• Daily weight-bearing physical activity
• Avoid thiazide diuretics
• Oral bisphosphonates or raloxifene (in postmenopausal women)
• Cinacalcet (proven to reduce PTH and calcium)

Malignancy-Related Hypercalcemia

• Treat the underlying malignancy as definitive therapy
• IV bisphosphonates (zoledronate preferred) for acute control
• Denosumab for RANK ligand-mediated or bisphosphonate-refractory cases
• For PTHrP-mediated: anti-PTHrP monoclonal antibodies (under evaluation)
• For lymphoma-related: glucocorticoids + bisphosphonates

Vitamin D-Mediated / Granulomatous Disease

• Glucocorticoids are first-line (reduce 1,25-OH vitamin D synthesis)
• Avoid sun exposure and dietary calcium restriction
• Hydroxychloroquine in steroid-sparing situations (sarcoidosis)

Quick Reference - Pharmacologic Summary Table

Key Clinical Pearls

1. Saline rehydration always comes first - hypercalcemia causes nephrogenic diabetes insipidus and osmotic diuresis, virtually all patients are volume-depleted
2. Loop diuretics are NOT routine - use only after full rehydration and only in life-threatening cases; forced diuresis protocols are largely abandoned
3. Calcitonin + bisphosphonate combination provides the fastest sustained response - calcitonin bridges the gap while bisphosphonate takes effect
4. Denosumab over bisphosphonate when GFR <30 mL/min
5. Glucocorticoids are the drug of choice in granulomatous disease and hematologic malignancies
6. Treat the underlying cause - all pharmacologic measures are temporizing without addressing the root etiology